We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-18.67%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$70.1M
AUM Growth
-$25.1M
Cap. Flow
+$1.55M
Cap. Flow %
2.22%
Top 10 Hldgs %
77.51%
Holding
34
New
3
Increased
3
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$10.8M
2
QLTI
QLT Inc
QLTI
+$183K
3
ZGNX
Zogenix, Inc.
ZGNX
+$10.8K

Top Sells

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$3.36M
2
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$2.87M
3
TWM icon
ProShares UltraShort Russell2000
TWM
+$1.9M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$534K
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$385K

Sector Composition

Rank Sector Weight
1 Healthcare 76.73%
2 Miscellaneous 23.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.69B
$12.4M 17.75%
315,000
+190,000
+152% +$10.8M
AMRI
2
DELISTED
Albany Molecular Research Inc
AMRI
$7.01M 10%
402,400
-165,000
-29% -$3.36M
AZN icon
3
AstraZeneca
AZN
$255B
$6.36M 9.08%
100,000
– –
QLTI
4
DELISTED
QLT Inc
QLTI
$5.74M 8.18%
2,157,200
+50,000
+2% +$183K
PFE icon
5
Pfizer
PFE
$160B
$4.71M 6.72%
158,100
– –
DGX icon
6
Quest Diagnostics
DGX
$27B
$4.07M 5.8%
66,208
– –
MNKD icon
7
PUT
MannKind Corp
MNKD
$1.31B
$3.85M 5.49%
240,000
-54,000
-18% -$1.15M
GSK icon
8
CALL
GSK
GSK
$101B
$3.85M 5.48%
+80,000
New +$4.16M
AORT icon
9
Artivion
AORT
$1.3B
$3.6M 5.13%
370,000
– –
AGN
10
DELISTED
Allergan plc
AGN
$2.72M 3.88%
10,000
– –
TWM icon
11
CALL
ProShares UltraShort Russell2000
TWM
$44M
$2.17M 3.09%
2,500
-2,500
-50% -$1.9M
TWM icon
12
ProShares UltraShort Russell2000
TWM
$44M
$2.17M 3.09%
2,500
-2,500
-50% -$1.9M
VTRS icon
13
CALL
Viatris
VTRS
$19.4B
$2.01M 2.87%
+50,000
New +$2.79M
ABBV icon
14
AbbVie
ABBV
$456B
$1.36M 1.94%
25,000
– –
ADYX
15
DELISTED
Adynxx Inc
ADYX
$1.33M 1.9%
7,017
– –
ANIP icon
16
CALL
ANI Pharmaceuticals
ANIP
$1.69B
$988K 1.41%
+25,000
New +$1.42M
SEEL
17
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$949K 1.35%
1
– –
AMRN
18
CALL
Amarin Corp
AMRN
$299M
$772K 1.1%
20,000
– –
AEGR
19
DELISTED
Aegerion Pharmaceuticals
AEGR
$680K 0.97%
50,000
-30,000
-38% -$534K
CYTK icon
20
Cytokinetics
CYTK
$10.8B
$669K 0.95%
100,000
– –
FCSC
21
DELISTED
Fibrocell Science Inc.
FCSC
$569K 0.81%
9,851
-667
-6% -$59K
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
$430K 0.61%
31,850
+600
+2% +$10.8K
SRNE
23
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$420K 0.6%
50,000
– –
VIRX
24
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$365K 0.52%
2,143
-1,190
-36% -$429K
ARIA
25
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$292K 0.42%
50,000
-50,000
-50% -$385K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Healthcare Value Capital held 34 positions worth $70.1M, down 26% from $95.2M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Healthcare Value Capital's Q3 2015 filing shows 3 new, 3 increased, 8 reduced and 6 closed positions. The largest sale was Albany Molecular Research Inc, an estimated $3.36M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

  • Healthcare Value Capital added most to ANI Pharmaceuticals in Q3 2015, an estimated $10.8M increase.
  • Healthcare Value Capital's biggest Q3 2015 reduction was Albany Molecular Research Inc, cutting an estimated $3.36M.
  • Healthcare Value Capital fully exited ProShares UltraShort NASDAQ Biotechnology in Q3 2015, selling an estimated $2.87M.
  • Healthcare Value Capital's ten largest holdings make up 78% of its $70.1M portfolio in Q3 2015.
  • Healthcare Value Capital opened 3 new positions and closed 6 in Q3 2015.
  • Healthcare Value Capital's portfolio value fell 26% quarter-over-quarter to $70.1M.

Based on Healthcare Value Capital's 13F filing for Q3 2015, filed 16 Nov 2015.